11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 31.03.2026 Expectation: 2100 pips
Investing in USDCAD with 1.38800 in sight
Today at 10:24 AM 12
Gold buy
Period: 06.03.2026 Expectation: 1200 pips
Accumulate gold up to $5,200 per ounce
Today at 07:58 AM 20
Brent sell
Period: 31.03.2026 Expectation: 150 pips
Selling Brent crude from $72.0
Today at 07:58 AM 12
Period: 31.08.2026 Expectation: 8000 pips
Buying USDJPY on stubborn US inflation
Today at 04:30 AM 17
Period: 31.08.2026 Expectation: 700 pips
Building medium-term buy position in NVIDIA
Today at 04:29 AM 10
Period: 09.03.2026 Expectation: 13000 pips
Investing in BTCUSD with $81,500 in view
Yesterday at 11:30 AM 34
Go to forecasts